Literature DB >> 21031061

Significance of t (8: 14) in CLL?

K C Lakshmaiah1, S Tejinder, Prasanna Kumari, Mangala M Gowri, C T Satheesh, D Lokanatha, Abraham L Jacob.   

Abstract

Entities:  

Year:  2010        PMID: 21031061      PMCID: PMC2955949          DOI: 10.4103/0971-6866.69374

Source DB:  PubMed          Journal:  Indian J Hum Genet        ISSN: 1998-362X


× No keyword cloud information.
Sir, The Burkitt’s lymphoma-type chromosomal translocations such as t (8; 14), t (8; 22) or t (2; 8) are rarely seen in chronic lymphocytic leukemia (CLL) and their significance remains poorly understood. On reviewing the literature, t (8; 14) and t (8; 22) were reported in eight CLL cases each; and t (2; 8) has been reported in two CLL cases.[1] A 65-year-old male presented with leukocytes, in October 2003, at the time of the routine check-up for weakness and fatigability. Peripheral blood cell count showed WBC: 82.6 × 109/l, Hb: 8.1 g/dl, platelets: 93 × 109/l with mature lymphocytes, which accounted for 86% of the differential. The bone marrow aspirates (BMA) were hypercellular with 63% of morphologically mature lymphocytes. Immunophenotyping revealed that such cells were positive for monotypic Igĸ light chain, CD5, CD19, CD20, CD23 and negative for CD10 and FMC7. Cytogenetic analysis performed on BMA showed normal karyotype. Physical examination revealed bilateral cervical lymphadenopathy and ultrasonogram of abdomen showed no hepatosplenomegaly. A diagnosis of CLL was made and according to modified Rai classification, his stage was IV (high risk). The patient was given chlorambucil orally and he obtained complete remission about 12 months later. He was on regular follow up after that, when in August 2007, he came with complaints of generalized lymphadenopathy and splenomegaly. Peripheral blood cell count showed WBC: 68.6 × 109/l, Hb: 9.1 g/dl, platelets: 88 × 109/l with mature lymphocytes, which accounted for 80% of the differential. BMA was hypercellular with 73% of morphologically mature lymphocytes. ZAP70 and CD38 were negative. Cytogenetic analysis revealed 45, XY, t(8;14)(q24;q32),-13, add (17)(p11)/46,XY [Figure 1] (ISCN-2005). Patient was restarted on chlorambucil and achieved remission in 8 months. He is presently doing well and on a regular follow-up.
Figure 1

GTG-banded metaphases showing 45, XY, t (8;14)(q24;q32),-13, add (17)(p11)/46, XY

GTG-banded metaphases showing 45, XY, t (8;14)(q24;q32),-13, add (17)(p11)/46, XY The rarity of t (8; 14) in CLL our patient persuaded us to explore the literature. After our case, there are now nine cases of t (8; 14) reported in literature. Only one case had no additional or complex karyotypic anomalies and one case transformed to Burkitt’s leukemia. Occurrence of this abnormality in CLL is rare, and the significance of this is unclear. Our patient is doing well in spite of new cytogenetic anomaly detected during relapse, which may be explained that other factors like ZAP70 and CD38 were negative and are related with poor prognosis.[23] Further studies of similar cases may shed additional insight into Burkitt’s lymphoma-type chromosomal translocations.
  3 in total

1.  Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia.

Authors:  Hai-Ping Dai; Yong-Quan Xue; Jun Zhang; Ya-Fang Wu; Jin-Lan Pan; Yong Wang; Juan Shen
Journal:  Acta Haematol       Date:  2009-02-25       Impact factor: 2.195

2.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

Authors:  G Juliusson; D G Oscier; M Fitchett; F M Ross; G Stockdill; M J Mackie; A C Parker; G L Castoldi; A Guneo; S Knuutila; E Elonen; G Gahrton
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

3.  Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

Authors:  R Schroers; F Griesinger; L Trümper; D Haase; B Kulle; L Klein-Hitpass; L Sellmann; U Dührsen; J Dürig
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.